Abeona Therapeutics (NASDAQ:ABEO) SVP Brendan O’malley Sells 13,578 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) SVP Brendan O’malley sold 13,578 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $72,370.74. Following the completion of the transaction, the senior vice president directly owned 451,134 shares of the company’s stock, valued at approximately $2,404,544.22. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Abeona Therapeutics Price Performance

Shares of ABEO traded up $0.05 during mid-day trading on Thursday, hitting $5.36. 1,363,791 shares of the company traded hands, compared to its average volume of 982,818. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $290.46 million, a price-to-earnings ratio of 4.36 and a beta of 1.12. The business has a 50-day moving average of $5.07 and a 200 day moving average of $5.64. Abeona Therapeutics Inc. has a one year low of $3.93 and a one year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, equities analysts expect that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC boosted its stake in Abeona Therapeutics by 19.6% during the 3rd quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 4,127 shares during the last quarter. Creative Planning increased its stake in Abeona Therapeutics by 43.0% in the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 4,305 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new stake in Abeona Therapeutics in the second quarter worth $25,000. Legal & General Group Plc acquired a new stake in Abeona Therapeutics in the second quarter worth $27,000. Finally, Riverwater Partners LLC boosted its position in shares of Abeona Therapeutics by 45.6% during the third quarter. Riverwater Partners LLC now owns 15,857 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 4,963 shares in the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABEO has been the topic of several recent research reports. Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings downgraded shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research note on Monday, October 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.